Trimodally treatment for stage IIIa NSCLC patients increases survival while not effecting surgical mortality or complexity

Por Dan Aravot, Yaron D. Barac, Efrat Krutzwald-Josefson, Aaron M. Allen, Dov Flex, Nir Peled, Mordechai R. Kramer, Yuri Peysakhovich, Milton Saute
Publicado em 2019-01-01